18 June
2024
PureTech Health plc
PureTech Founded Entity
Seaport Therapeutics Appoints Seasoned Executives to Management
Team
Antony Loebel, M.D., CNS
drug development expert and former CEO and CMO at Sunovion
Pharmaceuticals, appointed as Seaport's Chief Medical Officer and
President of Clinical Development
Lana Gladstein, J.D.,
experienced attorney across all legal matters, including corporate
governance, M&A transactions, alliance management and
intellectual property, joins Seaport as General
Counsel
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, noted that
its Founded Entity, Seaport
Therapeutics, a biopharmaceutical
company that is advancing novel neuropsychiatric medicines with a
proven strategy and team, today announced
it has expanded its executive team with the appointment of Antony
Loebel, M.D., as Chief Medical Officer and President of Clinical
Development, and Lana Gladstein, J.D., as General
Counsel.
Dr. Loebel was most recently the
President and Chief Executive Officer of Sunovion Pharmaceuticals,
a global pharmaceutical company focused on CNS
drug development and commercialization,
from 2019 to 2023. He served as the company's Chief Medical
Officer from 2011 to 2019. Dr. Loebel was instrumental in the
growth of Sunovion from a small to mid-size company with over $2.5
billion in net revenue. He played a key role in the development and
commercialization of LATUDA® for the treatment of patients with
bipolar depression and schizophrenia, with the product achieving
commercial success in the U.S. and globally under his leadership.
Other products developed and approved under Dr. Loebel's leadership
included APTIOM® for partial-onset seizures and KYNMOBI® for the
treatment of "OFF" episodes in patients with Parkinson's disease.
Prior to Sunovion, Dr. Loebel's industry experience included drug
development and medical affairs roles at Dainippon Sumitomo Pharma
America and Pfizer, Inc. A board-certified psychiatrist, Dr. Loebel
is a Fellow of the American College of Neuropsychopharmacology and
a Life Fellow of the American Psychiatric Association. He has
received multiple recognitions and awards including the
International Society of CNS Drug Development's 20th Anniversary
Award for a consistent
track record of innovation and leadership in CNS drug
development in 2022. He
was also named to PharmaVOICE's list of "100 Most
Inspiring People" in 2013 and 2019.
He received his M.D. from the University of
Washington School of Medicine.
Lana Gladstein joins Seaport as
General Counsel with over two decades
of legal expertise, including corporate governance, navigating M&A
transactions, licensing and partnerships, and intellectual property
matters. Most recently, she was the Group
General Counsel at APRINOIA Therapeutics, a clinical-stage company
developing therapeutics and diagnostics for neurodegenerative
diseases. Her prior roles include Chief Legal Officer at Recipharm
(Americas), Chief Legal Officer and General Counsel at Arranta Bio
(acquired by Recipharm), and Executive Vice
President, General Counsel and Officer at Brammer
Bio, (acquired by Thermo Fisher for $1.7 billion).
Prior to Brammer Bio, Ms. Gladstein was a partner
at Pepper Hamilton (now Troutman Pepper) and Nutter, and held
previous positions at Goodwin and Nixon Peabody, where she advised
life science companies on corporate and intellectual
property matters. She
holds a J.D. from Northeastern University School of Law and a B.A.
in biology from Brandeis
University.
The full text of the announcement
from Seaport is as follows:
Seaport Therapeutics Appoints
Seasoned Executives to Management Team
Antony Loebel, M.D., CNS
drug development expert and former CEO and CMO at Sunovion
Pharmaceuticals, appointed as Seaport's Chief Medical Officer and
President of Clinical Development
Lana Gladstein, J.D.,
experienced attorney across all legal matters, including corporate
governance, M&A transactions, alliance management and
intellectual property, joins Seaport as General
Counsel
BOSTON, June 18, 2024 - Seaport
Therapeutics, a clinical-stage
biopharmaceutical company that is advancing novel neuropsychiatric
medicines with a proven strategy and team, today announced it has
expanded its executive team with the appointment of Antony Loebel,
M.D., as Chief Medical Officer and President of Clinical
Development, and Lana Gladstein, J.D., as General Counsel.
Seaport's senior leadership team also includes Steven M. Paul, M.D., Founder and Chair of the Board of
Directors; Daphne Zohar, Founder, Chief Executive Officer and Board
Member; Eric Green, MBA, Chief Operating Officer; and
Michael Chen, Ph.D., Co-founder and Chief Scientific
Officer.
"I'm delighted to welcome two more
outstanding members to our senior executive team. As we design and
run studies to advance our clinical-stage pipeline of novel
therapeutics focused on important mental health conditions, Tony's
deep understanding of neuropsychiatric drug development builds on
our team's distinct advantages," said Daphne Zohar, Founder and
Chief Executive Officer of Seaport. "We are rapidly growing our
company and Lana's experience across all facets of legal, including
corporate governance, transactions, and IP, will be an important
resource to Seaport. I'm thrilled to have both Tony and Lana
onboard."
Dr. Loebel was most recently the
President and Chief Executive Officer of Sunovion Pharmaceuticals,
a global pharmaceutical company focused on CNS
drug development and commercialization,
from 2019 to 2023. He served as the company's Chief Medical
Officer from 2011 to 2019. Dr. Loebel was instrumental in the
growth of Sunovion from a small to mid-size company with over $2.5
billion in net revenue. He played a key role in the development and
commercialization of LATUDA® for the treatment of patients with
bipolar depression and schizophrenia, with the product achieving
commercial success in the U.S. and globally under his leadership.
Other products developed and approved under Dr. Loebel's leadership
included APTIOM® for partial-onset seizures and KYNMOBI® for the
treatment of "OFF" episodes in patients with Parkinson's disease.
Prior to Sunovion, Dr. Loebel's industry experience included drug
development and medical affairs roles at Dainippon Sumitomo Pharma
America and Pfizer, Inc. A board-certified psychiatrist, Dr. Loebel
is a Fellow of the American College of Neuropsychopharmacology and
a Life Fellow of the American Psychiatric Association. He has
received multiple recognitions and awards including the
International Society of CNS Drug Development's 20th Anniversary
Award for a consistent
track record of innovation and leadership in CNS drug
development in 2022. He
was also named to PharmaVOICE's list of "100 Most
Inspiring People" in 2013 and 2019.
He received his M.D. from the University of
Washington School of Medicine.
"I'm excited to join Daphne, Steve
and the rest of the incredible team at Seaport to help further
advance its robust pipeline of important neuropsychiatric
medicines," said Dr. Loebel. "We have a unique opportunity to make
a meaningful difference for the millions of people struggling with
serious mental health conditions, including depression and
anxiety."
Lana Gladstein joins Seaport as
General Counsel with over two decades
of legal expertise, including corporate governance, navigating M&A
transactions, licensing and partnerships, and intellectual property
matters. Most recently, she was the Group
General Counsel at APRINOIA Therapeutics, a clinical-stage company
developing therapeutics and diagnostics for neurodegenerative
diseases. Her prior roles include Chief Legal Officer at Recipharm
(Americas), Chief Legal Officer and General Counsel at Arranta Bio
(acquired by Recipharm), and Executive Vice
President, General Counsel and Officer at Brammer
Bio, (acquired by Thermo Fisher for $1.7 billion).
Prior to Brammer Bio, Ms. Gladstein was a partner
at Pepper Hamilton (now Troutman Pepper) and Nutter, and held
previous positions at Goodwin and Nixon Peabody, where she advised
life science companies on corporate and intellectual
property matters. She
holds a J.D. from Northeastern University School of Law and a B.A.
in biology from Brandeis
University.
"I am humbled and thrilled to be
joining the team at Seaport," said Ms. Gladstein. "This is a team
with an incredible track record of achievement and an unwavering
commitment to advancing innovative therapeutics for patients. I
look forward to leveraging my experience to build upon Seaport's
strong legal foundation and support its continued
growth."
About Seaport Therapeutics
Seaport Therapeutics is a
clinical-stage biopharmaceutical company advancing the development
of novel neuropsychiatric medicines in areas of high unmet patient
needs. The Company has a proven strategy of advancing clinically
validated mechanisms previously held back by limitations that are
overcome with its proprietary GlyphTM technology
platform. All the therapeutic candidates in its pipeline of first
and best-in-class medicines are based on the Glyph platform,
which is uniquely designed to enable oral
bioavailability, bypass first-pass metabolism and reduce
hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and
advanced important neuropsychiatric medicines and are guided by an
extensive network of renowned scientists, clinicians and key
opinion leaders. For more information, please visit
www.seaporttx.com.
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded Entities.
PureTech's R&D engine has resulted in the development of 29
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech
or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All
of the underlying programs and platforms that resulted in this
pipeline of therapeutic candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points.
For more information,
visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
statements that are or may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation those related to Seaport's
development plans and our future prospects, developments and
strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the
caption "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2023, filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the Company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US
Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com